Pharmaceuticals, Biotechnology and Life Sciences
Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of…
Zealand Pharma has reported positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes.
Neovacs’s Scientific Advisory Board has recommended extension of the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018.